Tagged with CBER

Denise Gavin – Director, Office of Gene Therapy & Steven Oh – Director, Office of Cellular Therapy and Human Tissue, OTP/CBER, FDA
US Pharma Roundup: Vinay Prasad Returns to FDA; Vaccine Task Force Revived
BIO2023: FDA CBER’s Peter Marks on COVID-19 Regulatory Impact
Peter Marks – Director, Center for Biologics Evaluation and Research (CBER), US FDA
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here